-
1
-
-
36549087247
-
Status of the epidemiology of atrial fibrillation
-
DOI 10.1016/j.mcna.2007.09.002, PII S0025712507001307, Atrial Fibrillation
-
Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008; 92 (1): 17-40. (Pubitemid 350182405)
-
(2008)
Medical Clinics of North America
, vol.92
, Issue.1
, pp. 17-40
-
-
Kannel, W.B.1
Benjamin, E.J.2
-
2
-
-
0037221236
-
Atrial fibrillation is associated with severe acute ischemic stroke
-
DOI 10.1159/000068743
-
Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology. 2003; 22 (2): 118-23. (Pubitemid 36302428)
-
(2003)
Neuroepidemiology
, vol.22
, Issue.2
, pp. 118-123
-
-
Dulli, D.A.1
Stanko, H.2
Levine, R.L.3
-
3
-
-
33746833635
-
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation)
-
DOI 10.1016/j.jacc.2006.07.009, PII S073510970601816X
-
Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation- executive summary: a report of the American College of Cardiology/ American heart association task force on practice guidelines and the European Society of cardiology committee for practice guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol. 2006; 48 (4): 854-906. (Pubitemid 44175743)
-
(2006)
Journal of the American College of Cardiology
, vol.48
, Issue.4
, pp. 854-906
-
-
Fuster, V.1
Ryden, L.E.2
Cannom, D.S.3
Crijns, H.J.4
Curtis, A.B.5
Ellenbogen, K.A.6
Halperin, J.L.7
Le Heuzey, J.-Y.8
Kay, G.N.9
Lowe, J.E.10
Olsson, S.B.11
Prystowsky, E.N.12
Tamargo, J.L.13
Wann, S.14
Smith Jr., S.C.15
Jacobs, A.K.16
Adams, C.D.17
Anderson, J.L.18
Antman, E.M.19
Halperin, J.L.20
Hunt, S.A.21
Nishimura, R.22
Ornato, J.P.23
Page, R.L.24
Riegel, B.25
Priori, S.G.26
Blanc, J.-J.27
Budaj, A.28
Camm, A.J.29
Dean, V.30
Deckers, J.W.31
Despres, C.32
Dickstein, K.33
Lekakis, J.34
McGregor, K.35
Metra, M.36
Morais, J.37
Osterspey, A.38
Tamargo, J.L.39
Zamorano, J.L.40
more..
-
4
-
-
0024543543
-
Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study
-
Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989; 1 (8631): 175-9. (Pubitemid 19038801)
-
(1989)
Lancet
, vol.1
, Issue.8631
, pp. 175-179
-
-
Petersen, P.1
Godtfredsen, J.2
Andersen, B.3
Boysen, G.4
Andersen, E.D.5
-
5
-
-
0025914693
-
Final results
-
Stroke Prevention in Atrial Fibrillation Study
-
Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84 (2): 527-539.
-
(1991)
Circulation
, vol.84
, Issue.2
, pp. 527-539
-
-
-
6
-
-
0025241137
-
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation
-
The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators
-
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990; 323 (22): 1505-1511.
-
(1990)
N Engl J Med
, vol.323
, Issue.22
, pp. 1505-1511
-
-
-
7
-
-
0025814587
-
Canadian atrial fibrillation anticoagulation (CAFA) study
-
Boysen G, Godtfredsen J, Andersen ED, Andersen B. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol. 1991; 18 (2): 349-55.
-
(1991)
J Am Coll Cardiol
, vol.18
, Issue.2
, pp. 349-355
-
-
Boysen, G.1
Godtfredsen, J.2
Andersen, E.D.3
Andersen, B.4
-
8
-
-
0026478818
-
Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators
-
Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators. N Engl J Med. 1992; 327 (20): 1406-12.
-
(1992)
N Engl J Med
, vol.327
, Issue.20
, pp. 1406-1412
-
-
Ezekowitz, M.D.1
Bridgers, S.L.2
James, K.E.3
-
9
-
-
0027505093
-
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
-
EAFT (European Atrial Fibrillation Trial) study group
-
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) study group. Lancet 1993; 342 (8882): 1255-1262.
-
(1993)
Lancet
, vol.342
, Issue.8882
, pp. 1255-1262
-
-
-
10
-
-
34347394385
-
Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
-
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146 (12): 857-67. (Pubitemid 351650486)
-
(2007)
Annals of Internal Medicine
, vol.146
, Issue.12
, pp. 857-867
-
-
Hart, R.G.1
Pearce, L.A.2
Aguilar, M.I.3
-
11
-
-
0033527355
-
Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis
-
Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: ameta-analysis. Ann Intern Med. 1999; 131 (7): 492-501. (Pubitemid 29482392)
-
(1999)
Annals of Internal Medicine
, vol.131
, Issue.7
, pp. 492-501
-
-
Hart, R.G.1
Benavente, O.2
McBride, R.3
Pearce, L.A.4
-
12
-
-
77952220109
-
Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation
-
Siddiqui FM, Qureshi AI. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation. Expert Opin Pharmacother. 2010; 11 (8): 1403-11.
-
(2010)
Expert Opin Pharmacother
, vol.11
, Issue.8
, pp. 1403-1411
-
-
Siddiqui, F.M.1
Qureshi, A.I.2
-
13
-
-
71849117615
-
Dabigatran versus warfarin in the treatment of acute venous thromboembolism
-
Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361 (24): 2342-52.
-
(2009)
N Engl J Med
, vol.361
, Issue.24
, pp. 2342-2352
-
-
Schulman, S.1
Kearon, C.2
Kakkar, A.K.3
-
14
-
-
77957029781
-
Friedman, dabigatran etexilate: Pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty
-
Eriksson BI, Friedman RJ. Friedman, dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. ClinAppl Thromb Hemost. 2009; 15 (Suppl 1): 25S-31S.
-
(2009)
ClinAppl Thromb Hemost
, vol.15
, Issue.SUPPL. 1
-
-
Eriksson, B.I.1
Friedman, R.J.2
-
15
-
-
57649123692
-
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
-
Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009; 24 (1): 1-9.
-
(2009)
J Arthroplasty
, vol.24
, Issue.1
, pp. 1-9
-
-
Ginsberg, J.S.1
Davidson, B.L.2
Comp, P.C.3
-
16
-
-
34548575058
-
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial
-
DOI 10.1016/S0140-6736(07)61445-7, PII S0140673607614457
-
Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, noninferiority trial. Lancet. 2007; 370 (9591): 949-56. (Pubitemid 47393577)
-
(2007)
Lancet
, vol.370
, Issue.9591
, pp. 949-956
-
-
Eriksson, B.I.1
Dahl, O.E.2
Rosencher, N.3
Kurth, A.A.4
Van Dijk, C.N.5
Frostick, S.P.6
Prins, M.H.7
Hettiarachchi, R.8
Hantel, S.9
Schnee, J.10
Buller, H.R.11
-
17
-
-
35449007749
-
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial
-
DOI 10.1111/j.1538-7836.2007.02748.x
-
Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007; 5 (11): 2178-85. (Pubitemid 47617868)
-
(2007)
Journal of Thrombosis and Haemostasis
, vol.5
, Issue.11
, pp. 2178-2185
-
-
Eriksson, B.I.1
Dahl, O.E.2
Rosencher, N.3
Kurth, A.A.4
Van Dijk, C.N.5
Frostick, S.P.6
Kalebo, P.7
Christiansen, A.V.8
Hantel, S.9
Hettiarachchi, R.10
Schnee, J.11
Buller, H.R.12
-
18
-
-
17644409026
-
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial
-
DOI 10.1111/j.1538-7836.2004.01100.x
-
Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005; 3 (1): 103-11. (Pubitemid 41647122)
-
(2005)
Journal of Thrombosis and Haemostasis
, vol.3
, Issue.1
, pp. 103-111
-
-
Eriksson, B.I.1
Dahl, O.E.2
Buller, H.R.3
Hettiarachi, R.4
Rosencher, N.5
Bravo, M.-L.6
Ahnfelt, L.7
Piovella, F.8
Stangier, J.9
Kalebo, P.10
Reilly, P.11
-
19
-
-
70349306707
-
Dabigatran versus warfarin in patients with atrial fibrillation
-
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361 (12): 1139-51.
-
(2009)
N Engl J Med
, vol.361
, Issue.12
, pp. 1139-1151
-
-
Connolly, S.J.1
Ezekowitz, M.D.2
Yusuf, S.3
-
20
-
-
0037171819
-
Structure-based design of novel potent nonpeptide thrombin inhibitors
-
DOI 10.1021/jm0109513
-
Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002; 45 (9): 1757-66. (Pubitemid 34415371)
-
(2002)
Journal of Medicinal Chemistry
, vol.45
, Issue.9
, pp. 1757-1766
-
-
Hauel, N.H.1
Nar, H.2
Priepke, H.3
Ries, U.4
Stassen, J.-M.5
Wienen, W.6
-
21
-
-
77952167209
-
Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor
-
Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009; 15: 9S-16S.
-
(2009)
Clin Appl Thromb Hemost
, vol.15
-
-
Stangier, J.1
Clemens, A.2
-
22
-
-
1842633720
-
Prevention of venous thromboembolism following orthopaedic surgery: Clinical potential of direct thrombin inhibitors
-
DOI 10.2165/00003495-200464060-00002
-
Eriksson BI, Dahl OE. Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors. Drugs. 2004; 64 (6): 577-95. (Pubitemid 38482439)
-
(2004)
Drugs
, vol.64
, Issue.6
, pp. 577-595
-
-
Eriksson, B.I.1
Dahl, O.E.2
-
23
-
-
46449119238
-
Dabigatran etexilate
-
DOI 10.1038/nrd2622, PII NRD2622
-
Eriksson BI, Smith H, Yasothan U, Kirkpatrick P. Dabigatran etexilate. Nat Rev Drug Discov. 2008; 7 (7): 557-8. (Pubitemid 351927721)
-
(2008)
Nature Reviews Drug Discovery
, vol.7
, Issue.7
, pp. 557-558
-
-
Eriksson, B.I.1
Smith, H.2
Yasothan, U.3
Kirkpatrick, P.4
-
25
-
-
34447522035
-
In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate
-
DOI 10.1160/TH07-03-0183
-
Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In vitro profile and ex vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007; 98 (1): 155-62. (Pubitemid 47078782)
-
(2007)
Thrombosis and Haemostasis
, vol.98
, Issue.1
, pp. 155-162
-
-
Wienen, W.1
Stassen, J.-M.2
Priepke, H.3
Ries, U.J.4
Hauel, N.5
-
26
-
-
49149130353
-
Dabigatran etexilate
-
Sanford M, Plosker GL. Dabigatran etexilate. Drugs. 2008; 68 (12): 1699-709.
-
(2008)
Drugs
, vol.68
, Issue.12
, pp. 1699-1709
-
-
Sanford, M.1
Plosker, G.L.2
-
27
-
-
34548031359
-
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
-
DOI 10.1111/j.1365-2125.2007.02899.x
-
Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007; 64 (3): 292-303. (Pubitemid 47283865)
-
(2007)
British Journal of Clinical Pharmacology
, vol.64
, Issue.3
, pp. 292-303
-
-
Stangier, J.1
Rathgen, K.2
Stahle, H.3
Gansser, D.4
Roth, W.5
-
28
-
-
37149005153
-
Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects
-
Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008; 47 (1): 47-59. (Pubitemid 350260888)
-
(2008)
Clinical Pharmacokinetics
, vol.47
, Issue.1
, pp. 47-59
-
-
Stangier, J.1
Stahle, H.2
Rathgen, K.3
Fuhr, R.4
-
29
-
-
77953168824
-
Dabigatran etexilate-anovel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
-
van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-anovel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103 (6): 1116-1127.
-
(2010)
Thromb Haemost
, vol.103
, Issue.6
, pp. 1116-1127
-
-
Van Ryn, J.1
Stangier, J.2
Haertter, S.3
-
30
-
-
77953161242
-
Laboratory monitoring of dabigatran during orthopedic surgery (abstract PP-WE-142)
-
Ulehlova J, Slavik L, Krcova V, et al. Laboratory monitoring of dabigatran during orthopedic surgery (abstract PP-WE-142). J Thromb Haemost. 2009; 7 (Suppl 2): 674.
-
(2009)
J Thromb Haemost
, vol.7
, Issue.SUPPL. 2
, pp. 674
-
-
Ulehlova, J.1
Slavik, L.2
Krcova, V.3
-
31
-
-
10844233894
-
The ecarin clotting time, a universal method to quantify direct thrombin inhibitors
-
DOI 10.1159/000081505
-
Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb. 2003; 33: 173-83. (Pubitemid 39664135)
-
(2003)
Pathophysiology of Haemostasis and Thrombosis
, vol.33
, Issue.4
, pp. 173-183
-
-
Nowak, G.1
-
32
-
-
84855225857
-
-
1/13/2011
-
Advisory Committee Briefing Document. 2010 1/13/2011]; Available from: http: //www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf.
-
(2010)
Advisory Committee Briefing Document
-
-
-
33
-
-
77957126877
-
Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran
-
De Smedt A, De Raedt S, Nieboer K, De Keyser J, Brouns R. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis. 2010; 30 (5): 533-534.
-
(2010)
Cerebrovasc Dis
, vol.30
, Issue.5
, pp. 533-534
-
-
De Smedt, A.1
De Raedt, S.2
Nieboer, K.3
De Keyser, J.4
Brouns, R.5
-
35
-
-
77952738550
-
Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor
-
Ammollo CT, Semeraro F, Incampo F, Semeraro N, Colucci M. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost. 2010; 8 (4): 790-8.
-
(2010)
J Thromb Haemost
, vol.8
, Issue.4
, pp. 790-798
-
-
Ammollo, C.T.1
Semeraro, F.2
Incampo, F.3
Semeraro, N.4
Colucci, M.5
-
36
-
-
33744482393
-
Argatroban tPA stroke study: Study design and results in the first treated cohort
-
DOI 10.1001/archneur.63.8.1057
-
Sugg RM, Pary JK, Uchino K, et al. Argatroban tPA stroke study: study design and results in the first treated cohort. Arch Neurol. 2006; 63 (8): 1057-62. (Pubitemid 44232309)
-
(2006)
Archives of Neurology
, vol.63
, Issue.8
, pp. 1057-1062
-
-
Sugg, R.M.1
Pary, J.K.2
Uchino, K.3
Baraniuk, S.4
Shaltoni, H.M.5
Gonzales, N.R.6
Mikulik, R.7
Garami, Z.8
Shaw, S.G.9
Matherne, D.E.10
Moye, L.A.11
Alexandrov, A.V.12
Grotta, J.C.13
-
37
-
-
77954700046
-
Dabigatran and stroke thrombolysis
-
Dempfle CE, Hennerici MG. Dabigatran and stroke thrombolysis. Cerebrovasc Dis. 2010; 30 (2): 203-5.
-
(2010)
Cerebrovasc Dis
, vol.30
, Issue.2
, pp. 203-205
-
-
Dempfle, C.E.1
Hennerici, M.G.2
-
38
-
-
78349313002
-
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: A subgroup analysis of the RE-LY trial
-
Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010; 9 (12): 1157-63.
-
(2010)
Lancet Neurol
, vol.9
, Issue.12
, pp. 1157-1163
-
-
Diener, H.C.1
Connolly, S.J.2
Ezekowitz, M.D.3
-
39
-
-
0030695063
-
Platelet activity of high-dose factor VIIa is independent of tissue factor
-
Monroe DM, Hoffman M, Oliver JA, et al. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997; 99: 542-7. (Pubitemid 27519853)
-
(1997)
British Journal of Haematology
, vol.99
, Issue.3
, pp. 542-547
-
-
Monroe, D.M.1
Hoffman, M.2
Oliver, J.A.3
Roberts, H.R.4
-
40
-
-
75549083726
-
Effect of recombinant activated Factor VII in critical bleeding: Clinical experience of asingle center
-
Sartori MT, Imbergamo S, Zanon E, et al. Effect of recombinant activated Factor VII in critical bleeding: clinical experience of asingle center. Clin Appl Thromb Hemost. 2009; 15: 628-35.
-
(2009)
Clin Appl Thromb Hemost
, vol.15
, pp. 628-635
-
-
Sartori, M.T.1
Imbergamo, S.2
Zanon, E.3
-
41
-
-
38349096220
-
Role of prothrombin complex concentrates in reversing warfarin anticoagulation: Areview of the literature
-
Leissinger CA, Blatt PM, Hoots WK, et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: areview of the literature. Am J Hematol. 2008; 83: 137-43.
-
(2008)
Am J Hematol
, vol.83
, pp. 137-143
-
-
Leissinger, C.A.1
Blatt, P.M.2
Hoots, W.K.3
-
42
-
-
70449555472
-
Management of major bleedings during anticoagulant treatment with the oral direct thrombin inhibitor ximelagatran or warfarin
-
Fernlö f G, Sjö strö m BM, Lindell KM, et al. Management of major bleedings during anticoagulant treatment with the oral direct thrombin inhibitor ximelagatran or warfarin. Blood Coagul Fibrinolysis. 2009; 20: 667-74.
-
(2009)
Blood Coagul Fibrinolysis
, vol.20
, pp. 667-674
-
-
Fernlöf, G.1
Sjöström, B.M.2
Lindell, K.M.3
-
43
-
-
77949421739
-
Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate
-
Stangier J, Rathgen K, Stähle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. Clin Pharmacokinet. 2010; 49: 259-68.
-
(2010)
Clin Pharmacokinet
, vol.49
, pp. 259-268
-
-
Stangier, J.1
Rathgen, K.2
Stähle, H.3
|